As the country ramps up its focus on new HIV prevention strategies, the launch in late January of a new South African-led HIV vaccine trial, BRILLIANT 011, in Cape Town, is not simply another research milestone, writes Theresa Rossouw in an opinion piece in The Star.
She writes:
The development, in fact, has genuine scientific and societal significance. It is important, however, to interpret this moment appropriately. This is not the announcement of a licensed vaccine, nor does it mean the challenge of HIV prevention has been solved.
Rather, it marks an important step in a long and complex scientific process. In that sense, it should inspire cautious optimism: optimism because progress is being made, and caution because HIV vaccine development remains one of the most difficult undertakings in biomedical science.
Over the past decade, the HIV field has seen remarkable advances in treatment.
Antiretroviral therapy has transformed HIV infection from what was once widely regarded as a fatal condition into a manageable chronic disease for many people with access to diagnosis, care and sustained treatment.
This is one of the great successes of modern medicine and public health. At the same time, we are entering an increasingly important era of prevention. Preventive strategies are becoming more sophisticated, longer-acting, and potentially more accessible to vulnerable and neglected populations.
Six-monthly lenacapavir as pre-exposure prophylaxis is one particularly exciting example of this shift, but such developments suggest that the future of HIV control will depend not only on treatment but also on a much stronger and more diversified prevention agenda.
And yet, even in this expanding prevention landscape, an HIV vaccine has long remained the holy grail. The reason is straightforward: a safe and effective vaccine would have the potential to alter the trajectory of the epidemic in a way that few other interventions can.
It would not replace existing prevention tools, such as condoms, testing, treatment, or PrEP, all of which remain essential.
But it could become a uniquely powerful addition to that toolbox, with the potential to reduce new infections at the population level, lessen long-term pressure on healthcare systems, and offer more durable protection across communities at high risk.
This is precisely why the BRILLIANT 011 trial matters. It reflects the continuation of a scientific effort that has required extraordinary persistence in the face of repeated challenges.
HIV is a particularly formidable virus. It mutates rapidly, displays immense genetic diversity, and has evolved multiple mechanisms to evade the host immune system.
Disappointing results
These features help explain why vaccine development has taken so long and why previous efforts have often yielded disappointing results.
However, such setbacks should not be interpreted as failures in any simplistic sense. In science, each trial contributes to the accumulation of knowledge, even if it does not immediately produce a usable product.
This latest trial builds on an impressive body of work to which South African scientists have made major contributions. In particular, South African researchers have played an important role in advancing our understanding of broadly neutralising antibodies, the rare antibodies capable of recognising and blocking multiple HIV variants.
These antibodies have become central to contemporary thinking about HIV vaccine design. This contribution is scientifically important, but it is also symbolically important: it demonstrates that South African science is helping to shape the direction of global HIV research, rather than merely responding to it.
There is also a public communication dimension that should not be overlooked. Public scepticism about HIV vaccine research is understandable. Communities have heard hopeful claims before, and many people are understandably wary of overstated promises.
This scepticism should not be dismissed.
Instead, it should be met with clear, honest, and respectful communication about what this trial is designed to do, its limitations, and why early-stage research remains valuable. Trust is built not through hype but through transparency.
That, ultimately, is the significance of this moment. Progress against HIV has never come from a single dramatic breakthrough. It has come from persistence, rigorous science, collaboration, and the willingness to keep building on each advance.
This new trial should be understood in exactly those terms: not as the end of the journey, but as a credible and important step forward. For South Africa, a country that knows the burden of HIV all too well, that is no small thing.
Theresa Rossouw – Professor in the Department of Immunology, University of Pretoria
The Star article – South Africa launches promising HIV vaccine trial, BRILLIANT 011 (Open access)
See more from MedicalBrief archives:
South Africa launches promising HIV vaccine trial, BRILLIANT 011
SA HIV vaccine trial picks up again after funding setback